← Back to Clinical Trials
Recruiting NCT07062380

NCT07062380 AI-Based Prediction of HCC Recurrence Patterns After Resection (APAR)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07062380
Status Recruiting
Phase
Sponsor Tongji Hospital
Condition Hepatecellular Carcinoma
Study Type OBSERVATIONAL
Enrollment 353 participants
Start Date 2025-06-10
Primary Completion 2026-06-10

Trial Parameters

Condition Hepatecellular Carcinoma
Sponsor Tongji Hospital
Study Type OBSERVATIONAL
Phase N/A
Enrollment 353
Sex ALL
Min Age 18 Years
Max Age 75 Years
Start Date 2025-06-10
Completion 2026-06-10
Interventions
Curative liver resectionReal-world multimodal therapy

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

This observational study aims to validate a deep learning model for predicting aggressive recurrence patterns in patients with early-stage liver cancer (HCC) after surgery. The main question it aims to answer is: Can the AI model accurately identify patients at high risk of cancer recurrence within 2 years after surgery? Participants will provide clinical data and undergo standard surgery, followed by 2-year imaging surveillance. Their data will be used for both AI prediction and validation of recurrence patterns.

Eligibility Criteria

Inclusion Criteria: * Aged 18-75 years, regardless of gender. * BCLC stage 0-A, scheduled for curative liver resection. * Preoperative clinical diagnosis of hepatocellular carcinoma (HCC). * Availability of dynamic contrast-enhanced MRI within 1 month before surgery, with acceptable image quality. * Child-Pugh liver function score ≤7. * ECOG Performance Status (PS) 0-1. * No severe organic diseases of the heart, lungs, brain, or other vital organs. Exclusion Criteria: * Concurrent other malignancies (except cured non-melanoma skin cancer or cervical carcinoma in situ). * Postoperative pathology confirms non-HCC diagnosis. * Pregnant or lactating women. * History of organ transplantation. * Inability to comply with the study protocol or follow-up schedule.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology